Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPLORENZI, Adriana T.FREGNANI, Jose Humberto T.POSSATI-RESENDE, Julio CesarANTONIAZZI, MarcioSCAPULATEMPO-NETO, CristovamSYRJANEN, StinaVILLA, Luisa L.LONGATTO-FILHO, Adhemar2016-12-202016-12-202016CANCER CYTOPATHOLOGY, v.124, n.8, p.581-588, 20161934-662Xhttps://observatorio.fm.usp.br/handle/OPI/17047BACKGROUNDHuman papillomavirus (HPV) DNA testing can be crucial for women who have limited access to traditional screening. The current study compared the results obtained through HPV DNA testing with those obtained through cytology-based screening. METHODSA total of 3068 women aged 18 to 85 years were enrolled in an opportunistic cervical cancer screening program developed by the Barretos Cancer Hospital and performed by a team of health professionals working within a mobile unit from March to December 2012, followed by statistical analyses. For each patient, 2 different cervical samples were collected and preserved in a careHPV assay and SurePath medium, respectively. RESULTSHigh-risk HPV (hr-HPV) DNA was detected in 10.0% of women, with the majority (86.7%) demonstrating no abnormal Papanicolaou test results. The following cytological samples were found to be hr-HPV positive: 8.2% of the normal samples; 39.4% of the samples with atypical squamous/glandular cells of undetermined significance; 38.5% of the samples with atypical squamous/glandular cells of undetermined significance, cannot exclude high-grade lesion; 55.3% of the samples with low-grade squamous intraepithelial lesions; and 100% of the samples with high-grade squamous intraepithelial lesions. Colposcopy examinations were performed among 33.4% of the women with positive results on at least 1 of the tests (HPV DNA positive and/or cytology with atypical squamous/glandular cells of undetermined significance, cannot exclude high-grade lesion or high-grade squamous intraepithelial lesions), and 59.5% of these women underwent biopsies. Among these samples, 18.2% were confirmed as cervical intraepithelial neoplasia. CONCLUSIONSThe careHPV test was demonstrated to be a feasible alternative to primary screening in low-resource settings accessed through the use of mobile units. Cancer Cytopathol 2016;124:581-8. (c) 2016 American Cancer Society. The human papillomavirus (HPV) DNA test is an important tool that is used to improve screening programs. The HPV DNA test allows for the detection of early HPV-induced lesions in women, thereby enabling clinicians to provide the best possible follow-up.engrestrictedAccesscancer screeningcervical cancercolposcopyhuman papillomavirus (HPV) DNA testsPapanicolaou testhuman-papillomavirus dnaself-collected specimens3+and cervical-cancerhybrid capture 2undetermined significancepositive womensquamous-cells5-year riskschinapapanicolaouarticleCopyright WILEY-BLACKWELL10.1002/cncy.21718OncologyPathology1934-6638